A novel schedule of accelerated partial breast radiation using intensity-modulated radiation therapy in elderly patients: survival and toxicity analysis of a prospective clinical trial.
- Author:
Mutlay SAYAN
1
;
Karen WILSON
;
Carl NELSON
;
Havaleh GAGNE
;
Deborah RUBIN
;
Ruth HEIMANN
Author Information
- Publication Type:Clinical Trial ; Original Article
- Keywords: Breast neoplasms; Intensity-modulated radiotherapy; Dose hypofractionation
- MeSH: Aged*; Appointments and Schedules*; Breast Neoplasms; Breast*; Dose Hypofractionation; Erythema; Follow-Up Studies; Humans; Mastectomy, Segmental; Prospective Studies*; Radiotherapy, Intensity-Modulated; Skin Pigmentation
- From:Radiation Oncology Journal 2017;35(1):32-38
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Several accelerated partial breast radiation (APBR) techniques have been investigated in patients with early-stage breast cancer (BC); however, the optimal treatment delivery techniques remain unclear. We evaluated the feasibility and toxicity of APBR delivered using intensity-modulated radiation therapy (IMRT) in elderly patients with stage I BC, using a novel fractionation schedule. MATERIALS AND METHODS: Forty-two patients aged ≥65 years, with stage I BC who underwent breast conserving surgery were enrolled in a phase I/II study evaluating APBR using IMRT. Forty eligible patients received 40 Gy in 4 Gy daily fractions. Patients were assessed for treatment related toxicities, and cosmesis, before APBR, during, and after completion of the treatment. RESULTS: The median age was 73 years, median tumor size 0.8 cm and the median follow-up was 54 months. The 5-year locoregional control was 97.5% and overall survival 90%. Erythema and skin pigmentation was the most common acute adverse event, reported by 27 patients (69%). Twenty-six patients (65%) reported mild pain, rated 1-4/10. This improved at last follow-up to only 2 (15%). Overall the patient and physician reported worst late toxicities were lower than the baseline and at last follow-up, patients and physicians rated cosmesis as excellent/good in 93% and 86 %, respectively. CONCLUSION: In this prospective trial, we observed an excellent rate of tumor control with daily APBR. The acceptable toxicity profile and cosmetic results of this study support the use of IMRT planned APBR with daily schedule in elderly patients with early stage BC.
